ProShare Advisors’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-20,894
| Closed | -$7K | – | 1781 |
|
|
2016
Q3 | $7K | Sell |
20,894
-1,536
| -7% | -$515 | ﹤0.01% | 1459 |
|
|
2016
Q2 | $10K | Buy |
22,430
+191
| +0.9% | +$85 | ﹤0.01% | 1581 |
|
|
2016
Q1 | $30K | Sell |
22,239
-1,302
| -6% | -$1.76K | ﹤0.01% | 1566 |
|
|
2015
Q4 | $35K | Buy |
23,541
+8,126
| +53% | +$12.1K | ﹤0.01% | 1688 |
|
|
2015
Q3 | $24K | Sell |
15,415
-4,993
| -24% | -$7.77K | ﹤0.01% | 1427 |
|
|
2015
Q2 | $35K | Sell |
20,408
-2,395
| -11% | -$4.11K | ﹤0.01% | 1626 |
|
|
2015
Q1 | $32K | Sell |
22,803
-2,540
| -10% | -$3.56K | ﹤0.01% | 1893 |
|
|
2014
Q4 | $38K | Sell |
25,343
-21,545
| -46% | -$32.3K | ﹤0.01% | 1933 |
|
|
2014
Q3 | $97K | Sell |
46,888
-10,629
| -18% | -$22K | ﹤0.01% | 2173 |
|
|
2014
Q2 | $176K | Sell |
57,517
-46,024
| -44% | -$141K | ﹤0.01% | 2223 |
|
|
2014
Q1 | $259K | Buy |
+103,541
| New | +$259K | ﹤0.01% | 2346 |
|
|
2013
Q4 | – | Sell |
-52,729
| Closed | -$120K | – | 2482 |
|
|
2013
Q3 | $120K | Buy |
+52,729
| New | +$120K | ﹤0.01% | 2368 |
|
ProShare Advisors's RXII Position: Q4 2016 in Review
ProShare Advisors sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 20,894 shares — an estimated $7K sold.
ProShare Advisors first reported a position in RXII in Q3 2013 and held it in 12 quarters. The position peaked at $259K in Q1 2014. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- ProShare Advisors reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- ProShare Advisors sold 20,894 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $7K.
- ProShare Advisors first reported a position in GALENA BIOPHARMA INC COM in Q3 2013 and held it in 12 quarters.
- ProShare Advisors's GALENA BIOPHARMA INC COM position peaked at $259K in Q1 2014.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on ProShare Advisors's 13F filing for Q4 2016, filed 13 Feb 2017.